摘要
基于中医气血相关理论,络病理论提出脑之气络与脉络相偕而行,在结构和功能方面“唇齿相依”,为脑主神明功能的重要基础;提出络气虚滞/郁滞、脉络瘀阻、神识失用为阿尔茨海默病主要病机,有别于现代医学重点关注神经元的研究策略;提出从神经元保护——清除β-淀粉样蛋白、磷酸化tau蛋白等病理产物和脑微血管保护——脑微血管结构与功能保护、促进治疗性血管新生、增加脑血流2个方面治疗阿尔茨海默病的必要性。在“络以通为用”治疗原则指导下研制的通络代表药物通心络胶囊具有微血管保护优势,可发挥血管保护介导的神经保护作用,临床研究证实其可有效治疗阿尔茨海默病、血管性痴呆及认知障碍相关疾病,可为从神经-血管保护全面防治阿尔茨海默病提供新思路和新途径。
Based on the correlation between Qi and blood in traditional Chinese medicine,the collateral disease theory puts forward that the Qi-collateral go hand in hand with the vessel-collateral of the brain,and to be as close as lips to teeth in structure and function,which is an important basis for the function of brain governing mind. And this theory proposes that deficiency/stagnancy of collateral-Qi,stagnation of collaterals and loss of consciousness are the main pathogenesis of Alzheimer’s disease(AD),which is different from the research strategy of modern medicine focusing on neurons. It is suggested that it is necessary to treat AD from two aspects,including neuronal protection(elimination of pathological products such as β-amyloid and phosphorylated tau protein)and cerebral microvascular protection(protection of cerebral microvascular structure and function,promotion of therapeutic angiogenesis and increase of cerebral blood flow. Tongxinluo capsules is a representative drug for dredging collaterals developed under the guidance of the therapeutic principle of collaterals need circulation,it can protect microvessels and play a neuroprotective role mediated by vascular protection. Clinical studies have confirmed that Tongxinluo capsules can effectively treat AD,vascular dementia and cognitive impairment related diseases,which can provide new ideas and effective treatment ways to prevent and treat AD from neurovascular protection in a comprehensive manner.
作者
常丽萍
张宝瑜
李梦南
高丽霓
马静
魏聪
CHANG Liping;ZHANG Baoyu;LI Mengnan;GAO Lini;MA Jing;WEI Cong(National Key Laboratory of Traditional Chinese Medicine(TCM)for Collateral Disease Research and Innovation,Shijiazhuang 050035,China;Hebei Yiling Medical Research Institute,Key Research Laboratory of National Administration of TCM(Cardiocerebral Vessel Collateral Disease),Hebei Key Laboratory of Collateral Disease,Shijiazhuang 050035,China;Hebei Yiling Hospital,WU Yiling Famous TCM Expert Inheritance Studio,Shijiazhuang 050090,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2023年第7期216-221,共6页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家重点研发计划“中医药现代化研究”重点专项资助项目(2017YFC1700500)
河北省络病重点实验室建设项目(20567627H)
河北省自然科学基金项目(H2022106065)
石家庄市复方中药新药技术创新中心建设项目(217790467B)。
